The Optimism Gap in Tobacco Harm Reduction

Recently, I listened to a fascinating conversation between behavioural scientist Arielle Selya and Communications advisor, Jim McCarthy, on a podcast produced by American Vapor Manufacturers.

The discussion covered many familiar topics in the tobacco harm reduction world: the quality of research, the politics of nicotine regulation, and the strange dynamics that shape the scientific literature around vaping. It was thoughtful, at times humorous, and occasionally a little exasperated. Toward the closing stages of the conversation, Jim mentioned something that stuck with me: optimism and pessimism. It was a small comment in the flow of a much larger discussion, but it triggered a broader reflection about the way debates around nicotine science often unfold. What struck me was not simply the disagreement between different camps, but the deeper philosophical divide that sits underneath it. Listening to them talk, I began thinking about something that rarely gets discussed explicitly in this field: the role of optimism and pessimism in science itself.

The debate around tobacco harm reduction (THR) is usually framed as a battle over evidence. One side cites toxicology studies, youth surveys, and laboratory findings suggesting risks associated with vaping. The other side points to epidemiological trends, smoking cessation data, and comparative risk analyses suggesting that non-combustible nicotine products could dramatically reduce smoking-related disease. On the surface, it appears to be a dispute about methodology and interpretation. But beneath the statistics and academic papers lies something deeper. In many ways, the conflict reflects two fundamentally different outlooks about human behaviour, technology, and the purpose of public health.

Tobacco harm reduction is built on a quietly optimistic premise. It begins with an uncomfortable reality: people use nicotine, and many struggle to quit. For decades, public health policy focused almost entirely on abstinence. Stop smoking completely. Quit nicotine entirely. If that goal proved difficult, the assumption was often that the individual had failed or simply needed stronger interventions. Harm reduction challenges that model. Instead of asking whether nicotine use can be eliminated, it asks whether the harm associated with that behaviour can be drastically reduced.

From that perspective, products such as e-cigarettes represent an opportunity. They are not harmless, but they do not rely on combustion, the process that produces the overwhelming majority of the toxins responsible for smoking-related disease. If smokers switch from combustible cigarettes to lower-risk alternatives, the potential health gains could be enormous. That view requires a certain degree of optimism. It assumes that innovation can improve outcomes even when risky behaviour continues to exist. It assumes that adults can evaluate information and make decisions about their own health. And it assumes that technological progress can sometimes solve problems that traditional policy approaches struggle to address.

This idea is not new to public health. Harm reduction has been applied successfully in many areas.

In the context of nicotine, vaping fits squarely within that tradition. But not everyone views it that way.

Within many tobacco control institutions, the prevailing outlook is far more pessimistic. In that framework, any new nicotine product is assumed to introduce new risks that could ultimately outweigh potential benefits. Young people will inevitably experiment with it. Non-smokers may become addicted. The tobacco industry might exploit the technology to rebuild its market. Smoking itself could be renormalised. From this perspective, the safest path is strict control or prohibition. The precautionary principle becomes the dominant guiding philosophy: if uncertainty exists, it is better to prevent possible harm than to risk unintended consequences.

In theory, the precautionary principle is sensible. But when applied without balance, it can easily slide into institutional pessimism. Every new technology is viewed primarily through the lens of potential disaster. Benefits are treated as speculative while harms are treated as inevitable. Innovation becomes something to restrain rather than something to evaluate.

This difference in outlook shapes the scientific conversation in subtle ways. Researchers bring assumptions into their work just like everyone else. Those assumptions influence which questions they ask, which risks they emphasise, and which interpretations feel intuitively convincing. Studies suggesting harm from vaping often receive immediate attention and extensive media coverage. Studies suggesting significant benefits are sometimes treated with greater scepticism or framed as inconclusive. Population-level declines in smoking in countries where vaping is widespread are frequently attributed to other policies rather than substitution effects.

None of this necessarily implies deliberate bias. It may simply reflect the gravitational pull of underlying beliefs. If a scientist begins from the assumption that vaping is likely harmful at a population level, then evidence supporting that view will feel more credible. Evidence suggesting large public health benefits may seem suspicious or incomplete. Two researchers can examine the same dataset and reach very different conclusions depending on the questions they ask. One might ask whether vaping is diverting young people away from smoking. Another might ask whether vaping could eventually lead them toward cigarettes. Both questions are valid, yet they arise from different expectations about how people behave.

Listening to Arielle Selya speak on the podcast reminded me that scientific views can evolve. She has often described how her own thinking changed over time as she examined the evidence more closely. That willingness to revisit assumptions is central to scientific progress. Yet in highly politicised areas of public health, changing one’s position can be socially and professionally difficult. Fields develop intellectual cultures. Certain views become dominant. Departing from them can invite criticism or exclusion.

The tobacco harm reduction debate has increasingly taken on this kind of tribal structure. On one side are researchers, clinicians, and consumer advocates who see vaping as a disruptive technology with the potential to accelerate the decline of smoking. On the other side are public health institutions and advocacy organisations that view vaping primarily as a new threat requiring strong intervention. Each side tends to interpret new evidence through its existing framework.

What makes this dynamic particularly interesting is that both groups believe they are defending public health. The disagreement is not about whether smoking is harmful. That point is universally accepted. The disagreement is about how societies should respond to new technologies that could alter the nicotine landscape. Should innovation be embraced cautiously but constructively? Or should it be restricted until every possible risk is eliminated?

In countries like Australia, the pessimistic model has largely dominated policy. Regulators assumed that widespread vaping would trigger a youth epidemic, renormalise smoking, and undermine decades of tobacco control progress. The regulatory response reflected those fears. Access to nicotine vaping products was heavily restricted and eventually moved toward outright retail prohibition. Yet the outcomes have not matched the expectations of a neatly controlled environment. Nicotine demand did not disappear. Instead, a vast illicit market emerged. Organised crime groups moved rapidly to supply both illicit tobacco and vapes. Enforcement agencies now spend enormous resources trying to contain a black market that continues to expand.

At the same time, debates about youth behaviour and smoking trends continue. Data is contested, interpretations differ, and the policy conversation remains highly polarised. But the underlying philosophical question remains largely unspoken: what role should optimism play in science and public health?

Optimism in this context does not mean ignoring risks. It does not mean assuming every new technology will deliver positive outcomes. Rather, it means remaining open to the possibility that progress can come from unexpected directions. It means allowing evidence to reshape existing beliefs instead of forcing evidence to fit established narratives.

Science at its best is neither optimistic nor pessimistic. It is curious. It tests ideas, revises theories, and moves forward through a constant process of questioning. Yet scientists are human beings working within institutions and cultural frameworks. Over time, those frameworks can become rigid. A field that once thrived on questioning assumptions can gradually shift toward defending them.

The conversation between Jim and Arielle reminded me how important intellectual humility is in this space. Both spoke about the value of open dialogue, the possibility of changing one’s mind, and the need to examine evidence honestly, even when it challenges prior beliefs. That spirit is essential if tobacco control is to navigate the rapidly changing nicotine landscape.

Tobacco harm reduction asks an uncomfortable but necessary question. If millions of people will continue using nicotine despite decades of anti-smoking campaigns, is it better to insist on total abstinence or to provide pathways toward dramatically safer alternatives?

Answering that question requires more than data. It requires a certain outlook on human behaviour and technological progress. It requires a willingness to believe that imperfect solutions can still produce enormous improvements in public health.

In other words, it requires a measure of optimism.

Without that optimism, science risks becoming less about discovery and more about defending existing positions. And if that happens, one of the most promising opportunities to reduce smoking-related disease in modern history could be delayed or dismissed not because the evidence failed, but because the mindset evaluating it was already decided.